Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > US$10 Billion is a typical estimate for a M&A in 2023

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 29, 2023 6:54pm

172 Views

Post# 35706575

RE:RE:RE:RE:US$10 Billion is a typical estimate for a M&A in 2023

As KPMG reported in its Biopharm Deal Trends Outlook for 2023, and continues to still apply, “ Currently there is a dearth of available quality mid and late-stage assets in oncology “ .

https://kpmg.com/kpmg-us/content/dam/kpmg/pdf/2023/biopharma-deal-trends-outlook.pdf

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing